FDA approves pembrolizumab with chemotherapy for …
On September 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Sep 18, 2024 · KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Phase 3 Keytruda, Chemo Mesothelioma Trial Shows Promise
Jun 26, 2023 · Pharmaceutical company Merck says use of its immunotherapy drug Keytruda in conjunction with chemotherapy increases the survival rate for people with advanced pleural mesothelioma, according to the latest results of a phase 3 clinical trial.
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic...
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly
Mar 10, 2023 · “Patients are in need of new treatments that can improve survival outcomes, and these positive results support the potential of KEYTRUDA in combination with chemotherapy as a first-line treatment for patients with the most common form of malignant mesothelioma.”
Keytruda Plus Chemo Approved for Malignant Pleural Mesothelioma
Sep 20, 2024 · The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Merck wins first FDA approval for Keytruda as a treatment for ...
Sep 18, 2024 · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer...
FDA Approves Pembrolizumab with Chemotherapy for …
On 17 September 2024, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Keytruda Plus Chemo Approved for Malignant Pleural Mesothelioma
Sep 19, 2024 · The FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy as first-line treatment for adults with malignant pleural mesothelioma.
FDA Approves Pembrolizumab Plus Pemetrexed and Platinum …
Sep 18, 2024 · Fda approves merck’s keytruda® (pembrolizumab) plus pemetrexed and platinum chemotherapy as first-line treatment for adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (mpm).